CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."

CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.